Notizie AIOM – anno XV – Pagina 2

15 Dicembre 2017

Expert Emphasizes Importance of Acalabrutinib Approval in MCL

December 14, 2017 - The treatment of patients with mantle cell lymphoma (MCL) has undergone immense progress in the past year, says Michael Wang, MD. One of the biggest developments was the recent FDA approval of acalabrutinib for patients with relapsed disease. The single-arm ...
Leggi tutto

15 Dicembre 2017

HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer

HER2 status is significant to trastuzumab therapy; however, it is difficult to determine HER2 status accurately with few pieces of biopsies from advanced gastric cancer (AGC) due to highly heterogeneity and invasive behaviour, which will be investigated in this study. Fifty-six ...
Leggi tutto

15 Dicembre 2017

A First-in-Human Phase 1 Study of Subcutaneous Outpatient Recombinant Human IL-15 (rhIL-15) in Adults with Advanced Solid Tumors

Preclinical data established Interleukin-15 as a homeostatic factor and powerful stimulator of NK and CD8+ T cell function, the basis for clinical testing. A first-in-human outpatient phase I dose escalation trial of subcutaneous (SC) rhIL-15 was conducted in refractory ...
Leggi tutto

15 Dicembre 2017

Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study

Refining the selection of HER2 positive metastatic gastric cancer patients candidates for trastuzumab is a challenge of precision oncology. Preclinical studies have suggested several genomic mechanisms of primary resistance, leading to activation of tyrosine kinase receptors ...
Leggi tutto

15 Dicembre 2017

Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer

Androgen-deprivation therapy (ADT), including enzalutamide, induces resistance in prostate cancer (PCa); ADT resistance is associated with neuroendocrine differentiation (NED) and tumor-associated macrophages (TAMs). This study aimed to investigate the association between ...
Leggi tutto

15 Dicembre 2017

11 dicembre 2017 – Nota Informativa Importante su Radio-223 dicloruro

15 Dicembre 2017

11 dicembre 2017 – FDA estende le indicazioni terapeutiche di Sunitinib

15 Dicembre 2017

11 dicembre 2017 – Procedura extra-sistema (II fase) – Pertuzumab in combinazione con Trastuzumab

15 Dicembre 2017

12 dicembre 2017 – Integrazione: Comunicazione procedimento Pay-Back 5% – nuove AIC anno 2016/2017

15 Dicembre 2017

13 dicembre 2017 – FDA approva il primo biosimilare per il trattamento di alcuni carcinomi mammari e gastrici

LAVORIAMO CON

News

“One Health for Breast Cancer”: LA PREVENZIONE DEL TUMORE AL SENO PASSA ANCHE DALL’AMBIENTE

Salute Donna Odv e Ipsen insieme per il Pink October: il camper della salute arriverà a l’Aquila per la prevenzione del tumore al seno

TUMORE METASTATICO DEL SENO: PDTA DEDICATI ATTIVI NEL 18% DEI CENTRI

SALUTE MENTALE: IN ITALIA SERVONO 2 MILIARDI DI EURO IN PIU’ PER LE CURE

ANMAR: IL PARLAMENTO DEVE ACCELERARE E APPROVARE IL DDL 946

13 OTTOBRE, GIORNATA NAZIONALE PER IL TUMORE AL SENO METASTATICO: COSA CHIEDONO LE PAZIENTI ALLE ISTITUZIONI

ROLANDO M. D’ANGELILLO NUOVO PRESIDENTE INCOMING DELLA SIUrO

Notizie AIOM – anno XV

Expert Emphasizes Importance of Acalabrutinib Approval in MCL

HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer

A First-in-Human Phase 1 Study of Subcutaneous Outpatient Recombinant Human IL-15 (rhIL-15) in Adults with Advanced Solid Tumors

Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study

Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer

11 dicembre 2017 – Nota Informativa Importante su Radio-223 dicloruro

11 dicembre 2017 – FDA estende le indicazioni terapeutiche di Sunitinib

11 dicembre 2017 – Procedura extra-sistema (II fase) – Pertuzumab in combinazione con Trastuzumab

12 dicembre 2017 – Integrazione: Comunicazione procedimento Pay-Back 5% – nuove AIC anno 2016/2017

13 dicembre 2017 – FDA approva il primo biosimilare per il trattamento di alcuni carcinomi mammari e gastrici